# Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer

> **NCT00070278** · PHASE3 · UNKNOWN · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 800 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** epirubicin hydrochloride
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** paclitaxel
- **GENETIC:** comparative genomic hybridization
- **GENETIC:** microarray analysis
- **GENETIC:** mutation analysis
- **PROCEDURE:** conventional surgery
- **PROCEDURE:** neoadjuvant therapy

## Key facts

- **NCT ID:** NCT00070278
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2005-01
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2013-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00070278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00070278, "Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00070278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*